-
This Cannabis-Based Drug Has Outperformed Pfizer's Lyrica In Clinical Trials: A New Dawn For Diabetic Nerve Pain Management?
Wednesday, May 31, 2023 - 2:13pm | 430Read More...Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a leading player in cannabinoid medicine research, has successfully demonstrated that its proprietary drug for diabetic nerve pain, ZLT-L-007, surpasses the efficacy of Pfizer Inc. (NYSE: PFE)'s market-leading drug, Lyrica. Shares of...
-
Analyst Prescribes Neutral Rating For Pfizer Shares
Thursday, July 20, 2017 - 10:57am | 298Read More...Previewing second-quarter results of Pfizer Inc. (NYSE: PFE), Credit Suisse prescribed a Neutral rating for the shares of the company, down from its previous Outperform rating. Pfizer is scheduled to release its second-quarter results at 7 a.m. ET on Aug. 1. Analysts led by Vamil Divan expect...
-
Citigroup Releases Pfizer Core Product Trends; Explains Price Target
Tuesday, October 26, 2010 - 7:41am | 143Read More...Citigroup has released its Pfizer, Inc. (NYSE: PFE) core product trends for the week ending 10/15/2010. Lipitor, Lyrica, Chantix and AriceptXR are among the drugs featured in the report. “We arrive at our $17 target price for Pfizer based on a relative P/E compared to the US Drug peer group,”...
-
Pfizer's Product Trends For The Week Ending 9/24
Wednesday, October 6, 2010 - 7:41am | 348Read More...Citigroup has issued a report on Pfizer's (NYSE: PFE) product trends for the week ending on 9/24. In the report, Citigroup writes "Lipitor NRx/TRx Share Was 21.5%(-5bps)/22.0%(-15bps). Lipitor YOY TRx's have declined -12% YTD. PFE took 5% & 6.9% price increases(PI's) on 7/1/10 & 1/1/10...
